EUVIMEDEUVIMED entdecken
Crossref

Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study

Gérard de Pouvourville, David Cunningham, Frank-Ulrich Fricke, Peter Lindgren, Lorenzo Mantovani, Linda A Murphy, Oriol Solà-Morales, Jorge Mestre-Ferrandiz, Ron Akehurst

Value in Health · 2023

DOI: 10.1016/j.jval.2023.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Gérard de Pouvourville und 8 weiteren Autor:innen. Beteiligte Einrichtung: ESSEC Business School, Cergy-Pontoise, France. Electronic address: pouvourville@essec.edu. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to describe the role of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) in 5 European countries and to identify the hurdles to the acceptance of RWE and suggest directions toward its more effective use. METHODS: Authors from France, Germany, Italy, and Sweden used a common template to extract evidence. For England, the Cancer Drugs Fund was described and analyzed as a particular model for the use of RWD to provide evidence for coverage decisions and managed entry agreements. RESULTS: In all countries except Germany, HTA bodies acknowledged the relevance of RWD/RWE to address postlaunch uncertainties. In Germany, evidence from randomized controlled trials remains the gold standard, and evidence based on RWD is generally rejected. Multiple sources of RWD exist, but the quality, the immediate relevance of existing sources, and their interoperability limit their adaptation to the specifics of a given drug. This leads to skepticism about the validity of the evidence. Timing is also a key issue: the production of evidence may not be synchronized with the HTA and pricing bodies' agendas. The Cancer Drugs Fund case emphasizes that a strong partnership among all stakeholders and a pragmatic use of existing data, alongside clinical evidence provided by companies, are key success factors. CONCLUSIONS: A continuous investment in national health information systems is a key issue for providing valid RWE. Processes and aids to guide the acceptability and usage of RWE derived from pairing between sources and questions are essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalHumansEuropeFranceGermanyItalySweden

Stichwörter der Autor:innen

country comparisonreal-world datareal-world evidence

Autor:innen und Institutionen

  • ESSEC Business School, Cergy-Pontoise, France. Electronic address: pouvourville@essec.edu.
  • ESSEC Business School, Cergy-Pontoise, France.

Zitieren

APA

de Pouvourville, G., Cunningham, D., Fricke, F. U., Lindgren, P., Mantovani, L., Murphy, L. A., Solà-Morales, O., Mestre-Ferrandiz, J., & Akehurst, R. (2023). Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. Value in Health. https://doi.org/10.1016/j.jval.2023.01.009

Vancouver

de Pouvourville G, Cunningham D, Fricke FU, Lindgren P, Mantovani L, Murphy LA, et al. Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. Value in Health. 2023. doi:10.1016/j.jval.2023.01.009

BibTeX
@article{dePouvourville2023,
  author = {de Pouvourville, Gérard and Cunningham, David and Fricke, Frank-Ulrich and Lindgren, Peter and Mantovani, Lorenzo and Murphy, Linda A and Solà-Morales, Oriol and Mestre-Ferrandiz, Jorge and Akehurst, Ron},
  title = {Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study},
  journal = {Value in Health},
  year = {2023},
  doi = {10.1016/j.jval.2023.01.009}
}
Kostenlos starten →